US Interim Financial Results Announcement on Form 6-K
Osmium pair pulls plug on board push.
Cash earnings were flat, and net interest margin rose slightly.
The pharmaceutical firm is pushing for approval of multiple phase-three trials in 2026.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details